Clinical trial Recruiting at 5 sites Observational Ages 30 to 99

Registry for Exablate Neuro treatment in Parkinson's Disease

Official title: A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

Run by InSightec · NCT05539196 · Data updated 2026-11-12

This study is tracking 60 people with advanced Parkinson's Disease to see how well a new treatment using the Exablate Neuro device works for those who haven't had success with medications.

Quick facts

Study typeObservational
Ages30 Years to 99 Years
SexAll
Enrollment60 (estimated)
SponsorInSightec
Industry-sponsored
Locations5 sites (Baltimore, Maryland and 4 other locations)
StatusRecruiting
StartedJanuary 23, 2023
Main results expectedJuly 31, 2029
Study endsJuly 31, 2029
Registry record updatedMarch 20, 2026
Trial IDNCT05539196 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men and women aged 30 years and older who are undergoing a planned Exablate procedure for their Parkinson's Disease.

Probably not a fit

Patients who do not agree to participate or are unlikely to complete the registry requirements will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, international observational registry that aims to collect data on patients undergoing unilateral pallidotomy using the Exablate Neuro device for advanced Parkinson's Disease with medication-refractory motor complications. The registry will enroll 60 subjects across approximately 10 centers worldwide and will follow participants for 5 years, with assessments at baseline, 3, 6, and 12 months, and annually thereafter. Data collected will include adverse events, medication usage, and various patient-reported outcomes to evaluate the treatment's effectiveness and safety.

Why it matters

Potential benefit: If successful, this registry could provide valuable insights into the long-term safety and effectiveness of the Exablate Neuro treatment for patients with advanced Parkinson's Disease.

How similar studies have gone: Other studies involving similar approaches to treating Parkinson's Disease have shown promise, but this registry specifically focuses on the Exablate Neuro device post-approval.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men and women, age 30 years and older.
* Subject undergoing a planned an Exablate procedure for their Parkinson's Disease with Motor Complications per local institution standard of care.
* Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all Registry visits.
* Subject has signed and received a copy of the approved informed consent form.

Exclusion Criteria:

* Subject does not agree to participate or is unlikely to participate for the entirety of the Registry.

Where it's running

  • University of Maryland, Baltimore
    Baltimore, Maryland, United States
    Recruiting
  • Weill Cornell Medicine
    New York, New York, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting
  • University of Texas Southwestern Medical Center
    Dallas, Texas, United States
    Recruiting
  • Ohnishi Neurological Center
    Akashi, Hyōgo, Japan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.